A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms. - Evans TRJ; Cook N; El-Khoueiry A; Pinato DJ; Tran NH; Hsiehchen D; Mena E; Meyer T; Wu J; Pathak SM; Paoletti C; Dutta L; et al. (British journal of cancer, 2026)